Geert Leenders

Geert Leenders

Auto-generated profile, based on publicly available information

Geert Leenders

Department of Cardiology, University Medical Center Utrecht, Utrecht, the Netherlands

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in International Journal of Cardiology
Verified
Journal Article
Closed access
FPFrancesco Ponticelli
Francesco Ponticelli
AKArif Azhar Khokhar
Arif Azhar Khokhar
GLGeert Leenders
Geert Leenders
MKMaayan Konigstein
Maayan Konigstein
Carlo ZivelonghiCarlo Zivelonghi
Carlo Zivelonghi
FGFrancesco Giannini
Francesco Giannini

1 July 2020 in The American Journal of Cardiology
Verified
Journal Article
Closed access
CZCarlo Zivelonghi
Carlo Zivelonghi
SVStefan Verheye
Stefan Verheye
LTLeo Timmers
Leo Timmers
JKJan Peter van Kuijk
Jan Peter van Kuijk
FGFrancesco Giannini
Francesco Giannini
PAPierfrancesco Agostoni
Pierfrancesco Agostoni

4 September 2020 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Open access
PDF file
NKNynke H. Kooistra
Nynke H. Kooistra
VIValent M. P. Intan‐Goey
Valent M. P. Intan‐Goey
FZFrancesca Ziviello
Francesca Ziviello
GLGeert E. Leenders
Geert E. Leenders
AKAdriaan O. Kraaijeveld
Adriaan O. Kraaijeveld
PSPieter R. Stella
Pieter R. Stella
Objectives: To compare the outcomes of transfemoral ACURATE neo (NEO) and Sapien 3 (S3) patients in terms of device success and clinical safety outcomes using a propensity score analysis.Background: Differences in clinical outcomes between the latest‐generation balloon‐expandable S3 and self‐expanding NEO in a “real‐world transfemoral TAVI population” are still unclear.Methods: We compared up to 6 months clinical outcomes using a propensity score analysis (inverse probability of treatment weighting [IPTW]) to account for differences in baseline characteristics.Results: A total of 345 patients underwent transfemoral transcatheter aortic valve implantation (TAVI) with either NEO or S3 at two centers in the Netherlands. Composite device success and early safety endpoints were comparable between NEO and S3 (Device success: IPTW‐adjusted OR: 0.35 [95% CI: 0.12–1.18], and early safety: IPTW‐adjusted OR: 0.51 [95% CI: 0.19–1.38]). Six‐months mortality was 5.3 versus 3.6%, stroke was 2.8 versus 3.3%, and pacemaker rate was 6.1 versus 8.6%, respectively with p = NS. Mean aortic gradient was lower in the NEO group (5.72 ± 2.47 vs. 9.05 ± 3.48; p = <.001), with a comparable rate of moderate or severe paravalvular leak (0 versus 2.1%; p = NS).Conclusions: Device success and clinical safety outcomes were comparable for both valves. Up to 6‐months follow‐up clinical outcomes and mortality rate remained excellent. Mean aortic gradient was lower after ACURATE neo implantation.

2 January 2019 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Open access
PDF file
RRRik Rozemeijer
Rik Rozemeijer
IMIvar G. van Muiden
Ivar G. van Muiden
SKStefan Koudstaal
Stefan Koudstaal
GLGeert E. Leenders
Geert E. Leenders
LTLeo Timmers
Leo Timmers
PSPieter R. Stella
Pieter R. Stella
Background: Polymer‐free amphilimus‐eluting stents (PF‐AES) represent a novel elution‐technology in coronary stenting. We aimed to assess 1‐year clinical outcomes of PF‐AES as compared to latest‐generation permanent polymer zotarolimus‐eluting stents (PP‐ZES) in a real‐world all‐comers setting.Methods: A prospective registry of patients treated with either PF‐AES or PP‐ZES between 2014 and 2016 was conducted. The primary outcome was defined as major adverse cardiac and cerebrovascular events (MACCE), and the secondary outcome was defined as target‐lesion failure (TLF) at 1 year. To account for measured confounders, a propensity‐score adjusted Cox proportional‐hazard model was built to evaluate clinical outcomes.Results: A total of 734 consecutive patients with 1,269 DES implantations were enrolled. The population was characterized by 28% diabetes, 24% ST‐segment elevation myocardial infarction, and a high number of complex lesions (69%). The rate of MACCE was 11.5% for PF‐AES and 13.6% for PP‐ZES, plog‐rank = 0.11. TLF was numerically lower in PF‐AES as compared to PP‐ZES (5.4 vs. 6.1%, plog‐rank = 0.68). After propensity‐score adjustment, PF‐AES showed a trend toward a lower rate of MACCE and a favorable rate of TLF as compared to PP‐ZES (HR 0.70; 95%CI 0.45 to 1.10, P = 0.12; and HR 0.88; 95%CI 0.47 to 1.65, P = 0.68, respectively). Rates of definite ST were low (0.8 vs. 0.3%, plog‐rank = 0.62).Conclusions: Our study suggests that implantation of PF‐AES was safe and effective in real‐world patients, with low‐rates of MACCE and TLF at 1 year. Our data needs to be confirmed by a large trial to evaluate the clinical outcomes of this novel polymer‐free, eluting‐technology used in PF‐AES.

19 November 2020 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
AWAdriaan Wilgenhof
Adriaan Wilgenhof
Carlo ZivelonghiCarlo Zivelonghi
Carlo Zivelonghi
SVStefan Verheye
Stefan Verheye
PVPaul Vermeersch
Paul Vermeersch
BSBenjamin Scott
Benjamin Scott
PAPierfrancesco Agostoni
Pierfrancesco Agostoni